Literature DB >> 18573174

Proteomics analysis in post-transplant lymphoproliferative disorders.

Yazan Alsayed1, Xavier Leleu, Alexey Leontovich, Ana B Oton, Mona Melhem, Diane George, Irene M Ghobrial.   

Abstract

Little is known about the biology of post-transplant lymphoproliferative disorders (PTLDs). The objective of this study was to determine the molecular alterations that occur at the protein level in patients with PTLDs. Six tumor samples from adult patients with PTLD and four benign lymph nodes were studied using protein microarray technique. Proteins that were dysregulated included proteins in the PI3K/mTOR, NFkB and HSP90 pathways. Inhibitors of these proteins induced cytotoxicity and apoptosis in EBV+ve and -ve cell lines. These results provide insight into pathways that are dysregulated in PTLD and can be targeted in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573174     DOI: 10.1111/j.1600-0609.2008.01106.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-06-05       Impact factor: 6.166

3.  The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation.

Authors:  Qian Wang; Nannan Zhu; Jiayuan Hu; Yan Wang; Jun Xu; Qiong Gu; Paul M Lieberman; Yan Yuan
Journal:  J Biol Chem       Date:  2020-04-20       Impact factor: 5.157

Review 4.  The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.

Authors:  XueQiao Liu; Jeffrey I Cohen
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

Review 5.  Epstein-Barr virus, rapamycin, and host immune responses.

Authors:  Sheri M Krams; Olivia M Martinez
Journal:  Curr Opin Organ Transplant       Date:  2008-12       Impact factor: 2.640

6.  Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Authors:  Adam X Sang; Marla C McPherson; Geoffrey T Ivison; Xiumei Qu; Joseph Rigdon; Carlos O Esquivel; Sheri M Krams; Olivia M Martinez
Journal:  Am J Transplant       Date:  2019-01-09       Impact factor: 8.086

7.  Utilising proteomic approaches to understand oncogenic human herpesviruses (Review).

Authors:  Christopher B Owen; David J Hughes; Belinda Baquero-Perez; Anja Berndt; Sophie Schumann; Brian R Jackson; Adrian Whitehouse
Journal:  Mol Clin Oncol       Date:  2014-07-09

Review 8.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.

Authors:  Chi Young Ok; Ling Li; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

9.  Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.

Authors:  Mohsen Navari; Fabio Fuligni; Maria A Laginestra; Maryam Etebari; Maria R Ambrosio; Maria R Sapienza; Maura Rossi; Giulia De Falco; Davide Gibellini; Claudio Tripodo; Stefano A Pileri; Lorenzo Leoncini; Pier P Piccaluga
Journal:  Front Microbiol       Date:  2014-12-23       Impact factor: 5.640

Review 10.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.